| Trial ID: | L4477 |
| Source ID: | NCT02133118
|
| Associated Drug: |
Individual Sus, Insulin, Pioglitazone
|
| Title: |
Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.
|
| Acronym: |
ZODIAC-39
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: individual SUs, insulin, pioglitazone
|
| Outcome Measures: |
Primary: The course of weight (Kg) after starting individual SU's, pioglitazone or insulin as add-on therapy., The course of the bodyweight up to five years after starting individual SU's (gliclazide/glibenclamide/tolbutamide/glimepiride), pioglitazone or insulin as add-on therapy, in metformin treated primary care patients with T2DM., Up to 5 years | Secondary: The course of the glycaemic control (HbA1c %) , up to five years after starting individual SU's, pioglitazone or insulin as add-on therapy., The course of the glycaemic control, up to five years after starting individual SU's (gliclazide, glibenclamide, tolbutamide, glimepiride), pioglitazone or insulin as add-on therapy, in metformin treated primary care patients with T2DM., Up to 5 years
|
| Sponsor/Collaborators: |
Sponsor: Medical Research Foundation, The Netherlands
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
16293
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
1998-01
|
| Completion Date: |
2014-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-03-17
|
| Locations: |
Isala, Zwolle, Overijssel, 8000 AB, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT02133118
|
